Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to <scp>HbA1c</scp> lowering in type 2 diabetes: An updated meta‐regression analysis incorporating <scp>FLOW</scp> and <scp>SOUL</scp> trials
HbA1c reduction, not bodyweight change, was significantly and proportionally associated with MACE risk reduction. HbA1c lowering may serve as a useful surrogate for the cardiovascular improvements associated with GLP-1RAs in type 2 diabetes.
Authors
- Satoshi Yoshiji (ORCID: https://orcid.org/0000-0001-8863-2413)
- Chen‐Yang Su (ORCID: https://orcid.org/0000-0001-6071-4660)
- Hiroto Minamino (ORCID: https://orcid.org/0000-0002-9113-4690)
- Nobuya Inagaki (ORCID: https://orcid.org/0000-0001-8261-2593)
- Daisuke Yabe (ORCID: https://orcid.org/0000-0002-5334-7687)
- Yamato Keidai (ORCID: https://orcid.org/0000-0001-6271-9609)
- Masashi Hasebe (ORCID: https://orcid.org/0000-0001-7031-2446)
Institutions
- Kyoto University (JP)
- McGill Genome Centre (CA)
- McGill University and Génome Québec Innovation Centre (CA)
- Kitano Hospital (JP)
- McGill University (CA)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1111/dom.70121
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47
Funders
- TD Bank
- Japan Student Services Organization
- Canadian Institutes of Health Research
- Fonds de Recherche du Québec - Santé